# Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

> **NCT00725803** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 33 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** GS-9450
- **DRUG:** GS-9450 Placebo

## Key facts

- **NCT ID:** NCT00725803
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-10
- **Final completion:** 2009-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725803, "Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00725803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*